샘플 요청 목록

 카트 문의
시장보고서
상품코드
1808821

봄철 각결막염 시장 : 성장, 전망, 경쟁 분석(2025-2033년)

Vernal Keratoconjunctivitis Market - Growth, Future Prospects and Competitive Analysis, 2025 - 2033
발행일: | 리서치사: Acute Market Reports | 페이지 정보: 영문 186 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 봄철 각결막염 시장은 알레르기성 안질환의 유병률 상승, 만성 안질환에 대한 의식 증가, 선진안과 치료 접근성 확대 등을 배경으로 2025년부터 2033년까지 연평균 복합 성장률(CAGR) 5.4%를 나타내 확대될 것으로 예측되고 있습니다. 봄철 각결막염(VKC)은 재발성이며 계절에 따라 악화되는 알레르기성 눈 질환으로, 특히 온난한 기후 지역에서 주로 소아와 젊은 성인이 앓습니다. 염증과 알레르기 반응을 표적으로 한 새로운 치료 개발과 함께 진단률의 상승이 시장의 꾸준한 성장을 지원하고 있습니다.

유병률의 상승과 치료의 진보가 성장을 견인

세계의 알레르기성 결막염의 이환율 증가는 VKC 치료 옵션에 대한 수요 증가에 기여합니다. 특히 아시아태평양과 중동에서는 도시화, 공해, 기후 변화 등의 요인으로 인해 취약한 사람들의 알레르기 반응이 높아지고 있습니다. 항히스타민제, 비만세포 안정화제, 코르티코스테로이드 제제의 치료 기술 혁신으로 치료 성적이 향상되고 있습니다. 표적 면역조절 요법과 생물학적 제제의 개발은 또한 안과 부위에 새로운 성장 기회를 제공합니다.

주요 과제로서의 안전에 대한 우려와 접근 장벽

시장 확대에도 불구하고 신흥국 시장에서는 진보된 치료에 대한 접근이 제한되고 있으며, 녹내장과 백내장의 위험 증가 등 코르티코스테로이드의 장기 사용과 관련된 안전성에 대한 우려가 과제가 되고 있습니다. 또한, 지역 간에 표준화된 치료 지침이 없습니다는 것은 첨단 치료의 채용을 방해하고 있습니다. 그러나 스테로이드를 절약할 수 있는 약물의 도입, 병용요법 증가, 안과를 중심으로 한 연구개발투자 증가에 의해 예측 기간 중에는 이러한 장벽이 완화될 것으로 예측됩니다.

질병 유형별 시장 세분화

시장은 사지 봄철 각결막염, 발근 봄철 각결막염, 혼합 봄철 각결막염으로 구분됩니다. 2024년, 사지 VKC는 열대·아열대 지역에서의 유병률이 높기 때문에 최대 시장 점유율을 차지했습니다. 발목 부위 VKC는 신진국 시장에서 특히 중요 진단을 개선하는 것이보고 사례를 뒷받침합니다. 혼합형 VKC는 빈도가 낮지만 보다 심각한 증상을 보이는 경우가 많으며, 병용 치료 전략이 필요합니다.

치료별 시장 세분화

치료는 비만 세포 안정화제, 항히스타민제, 코르티코스테로이드제, 비스테로이드성 항염증제(NSAIDs), 기타 요법으로 구분됩니다. 2024년에는 장기관리에 있어서의 안전성과 효능으로부터 비만세포안정제와 항히스타민제가 우위를 차지했습니다. 부신 피질 스테로이드는 여전히 심한 경우에 널리 처방되지만 부작용으로 인한 한계에 직면하고 있습니다. 비스테로이드성 항염증제(NSAIDs)는 증상 완화에 사용되고 있는 반면, 신흥 생물학적 제제 및 면역요법을 포함한 다른 부문들은 파이프라인 후보의 승인 획득과 함께 급성장할 것으로 예측됩니다.

지역별 인사이트

2024년에는 아시아태평양이 VKC 시장을 견인해 인도, 일본, 동남아시아에서 높은 유병률을 보이며 의료 인프라의 확대에 지지를 받았습니다. 뜨겁고 건조한 기후 때문에 VKC가 특히 많은 중동 및 아프리카가 이에 이어졌습니다. 유럽과 북미는 첨단 치료의 도입과 인지도 향상으로 큰 점유율을 차지하고 있습니다. 라틴아메리카는 진단 능력의 향상과 의약품의 보급에 의해 대두되고 있습니다.

경쟁 구도

2024년 시장은 세계적인 제약 선두와 각 지역 안과 전문의 모두가 적극적으로 활동하고 완만하게 통합되었습니다. 노발티스, 알콘, 참천 제약은 광범위한 안과용 의약품 포트폴리오와 혁신적인 제제로 시장을 선도하고 있습니다. Abbot Laboratories, Abby, Alagan, Bosh Health는 항히스타민 약물, 코르티코 스테로이드 및 지원 요법을 제공합니다. F. 호프만 라 로슈는 안과에 응용할 것으로 예상되는 생물학적 제형에 투자했습니다. 라보라트와르테아, 메다파머슈티컬즈, 천수제약, 선파마는 유럽과 아시아 전역에서 안과 분야에서의 지위를 강화했습니다. 테바파 매튜티컬스는 VKC 관리용 제네릭 의약품을 확대했습니다. 경쟁업체와의 차별화는 치료 효과, 안전성 프로파일, 파이프라인 혁신, 세계 유통 능력에 의해 형성됩니다.

목차

제1장 서문

  • 보고서의 내용
    • 보고서의 목적
    • 대상자
    • 주요 제공
  • 시장 세분화
  • 조사 방법
    • Phase I -2차 조사
    • Phase II - 1차 조사
    • Phase III - 전문가 패널 리뷰
    • 전제조건
    • 채용한 접근

제2장 주요 요약

제3장 봄철 각결막염 시장 : 경쟁 분석

  • 주요 공급업체의 시장 포지셔닝
  • 공급업체가 채용한 전략

제4장 봄철 각결막염 시장 : 매크로 분석과 시장 역학

  • 서론
  • 세계의 봄철 각결막염 시장 가치(2023-2033년)
  • 시장 역학
    • 시장 성장 촉진요인
    • 시장 성장 억제요인
    • 주요 과제
    • 주요 기회
  • 성장 촉진요인과 억제요인의 영향 분석
  • Porter's Five Forces 모델
    • 제산업체 파워
    • 바이어의 힘
    • 대체품의 위협
    • 신규 참가업체의 위협
    • 경쟁 기업 간 경쟁 관계
  • PESTEL 분석
    • 정치 상황
    • 경제 상황
    • 기술 상황
    • 법적 상황
    • 사회 상황

제5장 봄철 각결막염 시장 : 질환 유형별(2023-2033년)

  • 시장 개요
  • 성장·수익 분석 : 2024년 vs 2033년
  • 시장 세분화
    • 림발 봄철 각결막염
    • 타르살 봄철 각결막염
    • 혼합형 봄철 각결막염

제6장 봄철 각결막염 시장 : 치료별(2023-2033년)

  • 시장 개요
  • 성장·수익 분석 : 2024년 vs 2033년
  • 시장 세분화
    • 비만세포 안정제
    • 항히스타민제
    • 코르티코스테로이드
    • 비스테로이드성 항염증제
    • 기타

제7장 봄철 각결막염 시장 : 투여 경로별(2023-2033년)

  • 시장 개요
  • 성장·수익 분석 : 2024년 vs 2033년
  • 시장 세분화
    • 경구
    • 국소
    • 비경구

제8장 봄철 각결막염 시장 : 성별(2023-2033년)

  • 시장 개요
  • 성장·수익 분석 : 2024년 vs 2033년
  • 시장 세분화
    • 남성
    • 여성

제9장 봄철 각결막염 시장 : 유통 채널별(2023-2033년)

  • 시장 개요
  • 성장·수익 분석 : 2024년 vs 2033년
  • 시장 세분화
    • 병원 약국
    • 소매 약국
    • 온라인 약국

제10장 북미의 봄철 각결막염 시장(2023-2033년)

  • 시장 개요
  • 봄철 각결막염 시장 : 질환 유형별(2023-2033년)
  • 봄철 각결막염 시장 : 치료별(2023-2033년)
  • 봄철 각결막염 시장 : 투여 경로별(2023-2033년)
  • 봄철 각결막염 시장 : 성별(2023-2033년)
  • 봄철 각결막염 시장 : 유통 채널별(2023-2033년)
  • 봄철 각결막염 시장 : 지역별(2023-2033년)
    • 북미
      • 미국
      • 캐나다
      • 기타 북미

제11장 영국 및 유럽 연합의 봄철 각결막염 시장(2023-2033년)

  • 시장 개요
  • 봄철 각결막염 시장 : 질환 유형별(2023-2033년)
  • 봄철 각결막염 시장 : 치료별(2023-2033년)
  • 봄철 각결막염 시장 : 투여 경로별(2023-2033년)
  • 봄철 각결막염 시장 : 성별(2023-2033년)
  • 봄철 각결막염 시장 : 유통 채널별(2023-2033년)
  • 봄철 각결막염 시장 : 지역별(2023-2033년)
    • 영국 및 유럽 연합
      • 영국
      • 독일
      • 스페인
      • 이탈리아
      • 프랑스
      • 기타 유럽

제12장 아시아태평양의 봄철 각결막염 시장(2023-2033년)

  • 시장 개요
  • 봄철 각결막염 시장 : 질환 유형별(2023-2033년)
  • 봄철 각결막염 시장 : 치료별(2023-2033년)
  • 봄철 각결막염 시장 : 투여 경로별(2023-2033년)
  • 봄철 각결막염 시장 : 성별(2023-2033년)
  • 봄철 각결막염 시장 : 유통 채널별(2023-2033년)
  • 봄철 각결막염 시장 : 지역별(2023-2033년)
    • 아시아태평양
      • 중국
      • 일본
      • 인도
      • 호주
      • 한국
      • 기타 아시아태평양

제13장 라틴아메리카의 봄철 각결막염 시장(2023-2033년)

  • 시장 개요
  • 봄철 각결막염 시장 : 질환 유형별(2023-2033년)
  • 봄철 각결막염 시장 : 치료별(2023-2033년)
  • 봄철 각결막염 시장 : 투여 경로별(2023-2033년)
  • 봄철 각결막염 시장 : 성별(2023-2033년)
  • 봄철 각결막염 시장 : 유통 채널별(2023-2033년)
  • 봄철 각결막염 시장 : 지역별(2023-2033년)
    • 라틴아메리카
      • 브라질
      • 멕시코
      • 기타 라틴아메리카

제14장 중동 및 아프리카의 봄철 각결막염 시장(2023-2033년)

  • 시장 개요
  • 봄철 각결막염 시장 : 질환 유형별(2023-2033년)
  • 봄철 각결막염 시장 : 치료별(2023-2033년)
  • 봄철 각결막염 시장 : 투여 경로별(2023-2033년)
  • 봄철 각결막염 시장 : 성별(2023-2033년)
  • 봄철 각결막염 시장 : 유통 채널별(2023-2033년)
  • 봄철 각결막염 시장 : 지역별(2023-2033년)
    • 중동 및 아프리카
      • GCC
      • 아프리카
      • 기타 중동 및 아프리카

제15장 기업 프로파일

  • Abbott Laboratories
  • AbbVie
  • Alcon
  • Allergan
  • Bausch Health
  • F Hoffmann La Roche
  • Laboratoires Thea
  • Meda Pharmaceuticals
  • Novartis
  • Santen Pharmaceutical
  • Senju Pharmaceutical
  • Sun Pharma
  • Teva Pharmaceuticals
  • 기타 주요 기업
KTH 25.09.23

The global vernal keratoconjunctivitis (VKC) market is projected to expand at a CAGR of 5.4% from 2025 to 2033, driven by rising prevalence of allergic ocular diseases, growing awareness of chronic eye conditions, and expanding access to advanced ophthalmic therapies. VKC is a recurrent, seasonally aggravated allergic eye disorder that primarily affects children and young adults, particularly in warm climates. Increasing diagnosis rates, coupled with new treatment developments targeting inflammation and allergic responses, are supporting steady market growth.

Rising Prevalence and Therapeutic Advances Driving Growth

Growing incidence of allergic conjunctivitis worldwide is contributing to higher demand for VKC treatment options. Urbanization, pollution, and climate change factors have heightened allergic responses in vulnerable populations, especially in Asia Pacific and the Middle East. Pharmaceutical innovation in antihistamines, mast cell stabilizers, and corticosteroid formulations is improving treatment outcomes. The development of targeted immunomodulatory therapies and biologics is also creating new growth opportunities within the ophthalmology sector.

Safety Concerns and Access Barriers as Key Challenges

Despite market expansion, challenges include limited access to advanced treatments in developing regions and safety concerns associated with long-term corticosteroid use, such as increased risk of glaucoma and cataracts. The lack of standardized treatment guidelines across regions also hinders adoption of advanced therapies. However, the introduction of steroid-sparing drugs, increasing use of combination therapies, and rising ophthalmology-focused R&D investment are expected to mitigate these barriers over the forecast period.

Market Segmentation by Disease Type

The market is segmented into limbal vernal keratoconjunctivitis, tarsal vernal keratoconjunctivitis, and mixed vernal keratoconjunctivitis. In 2024, limbal VKC accounted for the largest market share due to its higher prevalence in tropical and subtropical regions. Tarsal VKC is also significant, particularly in developed markets where improved diagnosis is driving reported cases. Mixed VKC is less frequent but often presents with more severe symptoms, requiring combination treatment strategies.

Market Segmentation by Treatment

By treatment, the market is divided into mast cell stabilizers, antihistamines, corticosteroids, nonsteroidal anti-inflammatory drugs (NSAIDs), and other treatments. In 2024, mast cell stabilizers and antihistamines dominated due to their safety and effectiveness in long-term management. Corticosteroids remain widely prescribed for severe cases but face limitations due to side effects. NSAIDs are increasingly used for symptom relief, while the others segment, including emerging biologics and immunotherapies, is expected to grow rapidly as pipeline candidates gain approvals.

Regional Insights

In 2024, Asia Pacific led the VKC market, with high prevalence in India, Japan, and Southeast Asia, supported by expanding healthcare infrastructure. Middle East & Africa followed, where VKC is particularly common due to hot and dry climates. Europe and North America also accounted for significant shares, driven by advanced treatment adoption and greater awareness. Latin America is emerging, with rising diagnostic capacity and pharmaceutical penetration.

Competitive Landscape

The 2024 market was moderately consolidated, with both global pharmaceutical leaders and regional ophthalmic specialists active. Novartis, Alcon, and Santen Pharmaceutical led with broad ophthalmology portfolios and innovative formulations. Abbott Laboratories, AbbVie, Allergan, and Bausch Health offered antihistamines, corticosteroids, and supportive therapies. F. Hoffmann-La Roche invested in biologic therapies with potential ophthalmic applications. Laboratoires Thea, Meda Pharmaceuticals, Senju Pharmaceutical, and Sun Pharma strengthened their positions in ophthalmic segments across Europe and Asia. Teva Pharmaceuticals expanded generics for VKC management. Competitive differentiation is shaped by treatment efficacy, safety profiles, pipeline innovation, and global distribution capabilities.

Historical & Forecast Period

This study report represents an analysis of each segment from 2023 to 2033 considering 2024 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2025 to 2033.

The current report comprises quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends & technological analysis, case studies, strategic conclusions and recommendations and other key market insights.

Research Methodology

The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. The key data points that enable the estimation of Vernal Keratoconjunctivitis market are as follows:

Research and development budgets of manufacturers and government spending

Revenues of key companies in the market segment

Number of end users & consumption volume, price, and value.

Geographical revenues generated by countries considered in the report

Micro and macro environment factors that are currently influencing the Vernal Keratoconjunctivitis market and their expected impact during the forecast period.

Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top-down and bottom-up approach for validation of market estimation assures logical, methodical, and mathematical consistency of the quantitative data.

Market Segmentation

  • Disease Type
  • Limbal vernal keratoconjunctivitis
  • Tarsal vernal keratoconjunctivitis
  • Mixed vernal keratoconjunctivitis
  • Treatment
  • Mast cell stabilizers
  • Antihistamines
  • Corticosteroids
  • Nonsteroidal anti-inflammatory drugs
  • Other treatments
  • Route of Administration
  • Oral
  • Topical
  • Parenteral
  • Gender
  • Male
  • Female
  • Distribution Channel
  • Hospital pharmacies
  • Retail pharmacies
  • Online pharmacies
  • Region Segment (2023-2033; US$ Million)
  • North America
  • U.S.
  • Canada
  • Rest of North America
  • UK and European Union
  • UK
  • Germany
  • Spain
  • Italy
  • France
  • Rest of Europe
  • Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific
  • Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
  • Middle East and Africa
  • GCC
  • Africa
  • Rest of Middle East and Africa

Key questions answered in this report

  • What are the key micro and macro environmental factors that are impacting the growth of Vernal Keratoconjunctivitis market?
  • What are the key investment pockets concerning product segments and geographies currently and during the forecast period?
  • Estimated forecast and market projections up to 2033.
  • Which segment accounts for the fastest CAGR during the forecast period?
  • Which market segment holds a larger market share and why?
  • Are low and middle-income economies investing in the Vernal Keratoconjunctivitis market?
  • Which is the largest regional market for Vernal Keratoconjunctivitis market?
  • What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?
  • Which are the key trends driving Vernal Keratoconjunctivitis market growth?
  • Who are the key competitors and what are their key strategies to enhance their market presence in the Vernal Keratoconjunctivitis market worldwide?

Table of Contents

1. Preface

  • 1.1. Report Description
    • 1.1.1. Purpose of the Report
    • 1.1.2. Target Audience
    • 1.1.3. Key Offerings
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
    • 1.3.1. Phase I - Secondary Research
    • 1.3.2. Phase II - Primary Research
    • 1.3.3. Phase III - Expert Panel Review
    • 1.3.4. Assumptions
    • 1.3.5. Approach Adopted

2. Executive Summary

  • 2.1. Market Snapshot: Global Vernal Keratoconjunctivitis Market
  • 2.2. Global Vernal Keratoconjunctivitis Market, By Disease Type, 2024 (US$ Million)
  • 2.3. Global Vernal Keratoconjunctivitis Market, By Treatment, 2024 (US$ Million)
  • 2.4. Global Vernal Keratoconjunctivitis Market, By Route of Administration, 2024 (US$ Million)
  • 2.5. Global Vernal Keratoconjunctivitis Market, By Gender, 2024 (US$ Million)
  • 2.6. Global Vernal Keratoconjunctivitis Market, By Distribution Channel, 2024 (US$ Million)
  • 2.7. Global Vernal Keratoconjunctivitis Market, By Geography, 2024 (US$ Million)
  • 2.8. Attractive Investment Proposition by Geography, 2024

3. Vernal Keratoconjunctivitis Market: Competitive Analysis

  • 3.1. Market Positioning of Key Vernal Keratoconjunctivitis Market Vendors
  • 3.2. Strategies Adopted by Vernal Keratoconjunctivitis Market Vendors

4. Vernal Keratoconjunctivitis Market: Macro Analysis & Market Dynamics

  • 4.1. Introduction
  • 4.2. Global Vernal Keratoconjunctivitis Market Value, 2023 - 2033, (US$ Million)
  • 4.3. Market Dynamics
    • 4.3.1. Market Drivers
    • 4.3.2. Market Restraints
    • 4.3.3. Key Challenges
    • 4.3.4. Key Opportunities
  • 4.4. Impact Analysis of Drivers and Restraints
  • 4.5. Porter's Five Force Model
    • 4.5.1. Supplier Power
    • 4.5.2. Buyer Power
    • 4.5.3. Threat Of Substitutes
    • 4.5.4. Threat Of New Entrants
    • 4.5.5. Competitive Rivalry
  • 4.6. PESTEL Analysis
    • 4.6.1. Political Landscape
    • 4.6.2. Economic Landscape
    • 4.6.3. Technology Landscape
    • 4.6.4. Legal Landscape
    • 4.6.5. Social Landscape

5. Vernal Keratoconjunctivitis Market: By Disease Type, 2023-2033, USD (Million)

  • 5.1. Market Overview
  • 5.2. Growth & Revenue Analysis: 2024 Versus 2033
  • 5.3. Market Segmentation
    • 5.3.1. Limbal vernal keratoconjunctivitis
    • 5.3.2. Tarsal vernal keratoconjunctivitis
    • 5.3.3. Mixed vernal keratoconjunctivitis

6. Vernal Keratoconjunctivitis Market: By Treatment, 2023-2033, USD (Million)

  • 6.1. Market Overview
  • 6.2. Growth & Revenue Analysis: 2024 Versus 2033
  • 6.3. Market Segmentation
    • 6.3.1. Mast cell stabilizers
    • 6.3.2. Antihistamines
    • 6.3.3. Corticosteroids
    • 6.3.4. Nonsteroidal anti-inflammatory drugs
    • 6.3.5. Other treatments

7. Vernal Keratoconjunctivitis Market: By Route of Administration, 2023-2033, USD (Million)

  • 7.1. Market Overview
  • 7.2. Growth & Revenue Analysis: 2024 Versus 2033
  • 7.3. Market Segmentation
    • 7.3.1. Oral
    • 7.3.2. Topical
    • 7.3.3. Parenteral

8. Vernal Keratoconjunctivitis Market: By Gender, 2023-2033, USD (Million)

  • 8.1. Market Overview
  • 8.2. Growth & Revenue Analysis: 2024 Versus 2033
  • 8.3. Market Segmentation
    • 8.3.1. Male
    • 8.3.2. Female

9. Vernal Keratoconjunctivitis Market: By Distribution Channel, 2023-2033, USD (Million)

  • 9.1. Market Overview
  • 9.2. Growth & Revenue Analysis: 2024 Versus 2033
  • 9.3. Market Segmentation
    • 9.3.1. Hospital pharmacies
    • 9.3.2. Retail pharmacies
    • 9.3.3. Online pharmacies

10. North America Vernal Keratoconjunctivitis Market, 2023-2033, USD (Million)

  • 10.1. Market Overview
  • 10.2. Vernal Keratoconjunctivitis Market: By Disease Type, 2023-2033, USD (Million)
  • 10.3. Vernal Keratoconjunctivitis Market: By Treatment, 2023-2033, USD (Million)
  • 10.4. Vernal Keratoconjunctivitis Market: By Route of Administration, 2023-2033, USD (Million)
  • 10.5. Vernal Keratoconjunctivitis Market: By Gender, 2023-2033, USD (Million)
  • 10.6. Vernal Keratoconjunctivitis Market: By Distribution Channel, 2023-2033, USD (Million)
  • 10.7. Vernal Keratoconjunctivitis Market: By Region, 2023-2033, USD (Million)
    • 10.7.1. North America
      • 10.7.1.1. U.S.
        • 10.7.1.1.1. Vernal Keratoconjunctivitis Market: By Disease Type, 2023-2033, USD (Million)
        • 10.7.1.1.2. Vernal Keratoconjunctivitis Market: By Treatment, 2023-2033, USD (Million)
        • 10.7.1.1.3. Vernal Keratoconjunctivitis Market: By Route of Administration, 2023-2033, USD (Million)
        • 10.7.1.1.4. Vernal Keratoconjunctivitis Market: By Gender, 2023-2033, USD (Million)
        • 10.7.1.1.5. Vernal Keratoconjunctivitis Market: By Distribution Channel, 2023-2033, USD (Million)
      • 10.7.1.2. Canada
        • 10.7.1.2.1. Vernal Keratoconjunctivitis Market: By Disease Type, 2023-2033, USD (Million)
        • 10.7.1.2.2. Vernal Keratoconjunctivitis Market: By Treatment, 2023-2033, USD (Million)
        • 10.7.1.2.3. Vernal Keratoconjunctivitis Market: By Route of Administration, 2023-2033, USD (Million)
        • 10.7.1.2.4. Vernal Keratoconjunctivitis Market: By Gender, 2023-2033, USD (Million)
        • 10.7.1.2.5. Vernal Keratoconjunctivitis Market: By Distribution Channel, 2023-2033, USD (Million)
      • 10.7.1.3. Rest of North America
        • 10.7.1.3.1. Vernal Keratoconjunctivitis Market: By Disease Type, 2023-2033, USD (Million)
        • 10.7.1.3.2. Vernal Keratoconjunctivitis Market: By Treatment, 2023-2033, USD (Million)
        • 10.7.1.3.3. Vernal Keratoconjunctivitis Market: By Route of Administration, 2023-2033, USD (Million)
        • 10.7.1.3.4. Vernal Keratoconjunctivitis Market: By Gender, 2023-2033, USD (Million)
        • 10.7.1.3.5. Vernal Keratoconjunctivitis Market: By Distribution Channel, 2023-2033, USD (Million)

11. UK and European Union Vernal Keratoconjunctivitis Market, 2023-2033, USD (Million)

  • 11.1. Market Overview
  • 11.2. Vernal Keratoconjunctivitis Market: By Disease Type, 2023-2033, USD (Million)
  • 11.3. Vernal Keratoconjunctivitis Market: By Treatment, 2023-2033, USD (Million)
  • 11.4. Vernal Keratoconjunctivitis Market: By Route of Administration, 2023-2033, USD (Million)
  • 11.5. Vernal Keratoconjunctivitis Market: By Gender, 2023-2033, USD (Million)
  • 11.6. Vernal Keratoconjunctivitis Market: By Distribution Channel, 2023-2033, USD (Million)
  • 11.7. Vernal Keratoconjunctivitis Market: By Region, 2023-2033, USD (Million)
    • 11.7.1. UK and European Union
      • 11.7.1.1. UK
        • 11.7.1.1.1. Vernal Keratoconjunctivitis Market: By Disease Type, 2023-2033, USD (Million)
        • 11.7.1.1.2. Vernal Keratoconjunctivitis Market: By Treatment, 2023-2033, USD (Million)
        • 11.7.1.1.3. Vernal Keratoconjunctivitis Market: By Route of Administration, 2023-2033, USD (Million)
        • 11.7.1.1.4. Vernal Keratoconjunctivitis Market: By Gender, 2023-2033, USD (Million)
        • 11.7.1.1.5. Vernal Keratoconjunctivitis Market: By Distribution Channel, 2023-2033, USD (Million)
      • 11.7.1.2. Germany
        • 11.7.1.2.1. Vernal Keratoconjunctivitis Market: By Disease Type, 2023-2033, USD (Million)
        • 11.7.1.2.2. Vernal Keratoconjunctivitis Market: By Treatment, 2023-2033, USD (Million)
        • 11.7.1.2.3. Vernal Keratoconjunctivitis Market: By Route of Administration, 2023-2033, USD (Million)
        • 11.7.1.2.4. Vernal Keratoconjunctivitis Market: By Gender, 2023-2033, USD (Million)
        • 11.7.1.2.5. Vernal Keratoconjunctivitis Market: By Distribution Channel, 2023-2033, USD (Million)
      • 11.7.1.3. Spain
        • 11.7.1.3.1. Vernal Keratoconjunctivitis Market: By Disease Type, 2023-2033, USD (Million)
        • 11.7.1.3.2. Vernal Keratoconjunctivitis Market: By Treatment, 2023-2033, USD (Million)
        • 11.7.1.3.3. Vernal Keratoconjunctivitis Market: By Route of Administration, 2023-2033, USD (Million)
        • 11.7.1.3.4. Vernal Keratoconjunctivitis Market: By Gender, 2023-2033, USD (Million)
        • 11.7.1.3.5. Vernal Keratoconjunctivitis Market: By Distribution Channel, 2023-2033, USD (Million)
      • 11.7.1.4. Italy
        • 11.7.1.4.1. Vernal Keratoconjunctivitis Market: By Disease Type, 2023-2033, USD (Million)
        • 11.7.1.4.2. Vernal Keratoconjunctivitis Market: By Treatment, 2023-2033, USD (Million)
        • 11.7.1.4.3. Vernal Keratoconjunctivitis Market: By Route of Administration, 2023-2033, USD (Million)
        • 11.7.1.4.4. Vernal Keratoconjunctivitis Market: By Gender, 2023-2033, USD (Million)
        • 11.7.1.4.5. Vernal Keratoconjunctivitis Market: By Distribution Channel, 2023-2033, USD (Million)
      • 11.7.1.5. France
        • 11.7.1.5.1. Vernal Keratoconjunctivitis Market: By Disease Type, 2023-2033, USD (Million)
        • 11.7.1.5.2. Vernal Keratoconjunctivitis Market: By Treatment, 2023-2033, USD (Million)
        • 11.7.1.5.3. Vernal Keratoconjunctivitis Market: By Route of Administration, 2023-2033, USD (Million)
        • 11.7.1.5.4. Vernal Keratoconjunctivitis Market: By Gender, 2023-2033, USD (Million)
        • 11.7.1.5.5. Vernal Keratoconjunctivitis Market: By Distribution Channel, 2023-2033, USD (Million)
      • 11.7.1.6. Rest of Europe
        • 11.7.1.6.1. Vernal Keratoconjunctivitis Market: By Disease Type, 2023-2033, USD (Million)
        • 11.7.1.6.2. Vernal Keratoconjunctivitis Market: By Treatment, 2023-2033, USD (Million)
        • 11.7.1.6.3. Vernal Keratoconjunctivitis Market: By Route of Administration, 2023-2033, USD (Million)
        • 11.7.1.6.4. Vernal Keratoconjunctivitis Market: By Gender, 2023-2033, USD (Million)
        • 11.7.1.6.5. Vernal Keratoconjunctivitis Market: By Distribution Channel, 2023-2033, USD (Million)

12. Asia Pacific Vernal Keratoconjunctivitis Market, 2023-2033, USD (Million)

  • 12.1. Market Overview
  • 12.2. Vernal Keratoconjunctivitis Market: By Disease Type, 2023-2033, USD (Million)
  • 12.3. Vernal Keratoconjunctivitis Market: By Treatment, 2023-2033, USD (Million)
  • 12.4. Vernal Keratoconjunctivitis Market: By Route of Administration, 2023-2033, USD (Million)
  • 12.5. Vernal Keratoconjunctivitis Market: By Gender, 2023-2033, USD (Million)
  • 12.6. Vernal Keratoconjunctivitis Market: By Distribution Channel, 2023-2033, USD (Million)
  • 12.7. Vernal Keratoconjunctivitis Market: By Region, 2023-2033, USD (Million)
    • 12.7.1. Asia Pacific
      • 12.7.1.1. China
        • 12.7.1.1.1. Vernal Keratoconjunctivitis Market: By Disease Type, 2023-2033, USD (Million)
        • 12.7.1.1.2. Vernal Keratoconjunctivitis Market: By Treatment, 2023-2033, USD (Million)
        • 12.7.1.1.3. Vernal Keratoconjunctivitis Market: By Route of Administration, 2023-2033, USD (Million)
        • 12.7.1.1.4. Vernal Keratoconjunctivitis Market: By Gender, 2023-2033, USD (Million)
        • 12.7.1.1.5. Vernal Keratoconjunctivitis Market: By Distribution Channel, 2023-2033, USD (Million)
      • 12.7.1.2. Japan
        • 12.7.1.2.1. Vernal Keratoconjunctivitis Market: By Disease Type, 2023-2033, USD (Million)
        • 12.7.1.2.2. Vernal Keratoconjunctivitis Market: By Treatment, 2023-2033, USD (Million)
        • 12.7.1.2.3. Vernal Keratoconjunctivitis Market: By Route of Administration, 2023-2033, USD (Million)
        • 12.7.1.2.4. Vernal Keratoconjunctivitis Market: By Gender, 2023-2033, USD (Million)
        • 12.7.1.2.5. Vernal Keratoconjunctivitis Market: By Distribution Channel, 2023-2033, USD (Million)
      • 12.7.1.3. India
        • 12.7.1.3.1. Vernal Keratoconjunctivitis Market: By Disease Type, 2023-2033, USD (Million)
        • 12.7.1.3.2. Vernal Keratoconjunctivitis Market: By Treatment, 2023-2033, USD (Million)
        • 12.7.1.3.3. Vernal Keratoconjunctivitis Market: By Route of Administration, 2023-2033, USD (Million)
        • 12.7.1.3.4. Vernal Keratoconjunctivitis Market: By Gender, 2023-2033, USD (Million)
        • 12.7.1.3.5. Vernal Keratoconjunctivitis Market: By Distribution Channel, 2023-2033, USD (Million)
      • 12.7.1.4. Australia
        • 12.7.1.4.1. Vernal Keratoconjunctivitis Market: By Disease Type, 2023-2033, USD (Million)
        • 12.7.1.4.2. Vernal Keratoconjunctivitis Market: By Treatment, 2023-2033, USD (Million)
        • 12.7.1.4.3. Vernal Keratoconjunctivitis Market: By Route of Administration, 2023-2033, USD (Million)
        • 12.7.1.4.4. Vernal Keratoconjunctivitis Market: By Gender, 2023-2033, USD (Million)
        • 12.7.1.4.5. Vernal Keratoconjunctivitis Market: By Distribution Channel, 2023-2033, USD (Million)
      • 12.7.1.5. South Korea
        • 12.7.1.5.1. Vernal Keratoconjunctivitis Market: By Disease Type, 2023-2033, USD (Million)
        • 12.7.1.5.2. Vernal Keratoconjunctivitis Market: By Treatment, 2023-2033, USD (Million)
        • 12.7.1.5.3. Vernal Keratoconjunctivitis Market: By Route of Administration, 2023-2033, USD (Million)
        • 12.7.1.5.4. Vernal Keratoconjunctivitis Market: By Gender, 2023-2033, USD (Million)
        • 12.7.1.5.5. Vernal Keratoconjunctivitis Market: By Distribution Channel, 2023-2033, USD (Million)
      • 12.7.1.6. Rest of Asia Pacific
        • 12.7.1.6.1. Vernal Keratoconjunctivitis Market: By Disease Type, 2023-2033, USD (Million)
        • 12.7.1.6.2. Vernal Keratoconjunctivitis Market: By Treatment, 2023-2033, USD (Million)
        • 12.7.1.6.3. Vernal Keratoconjunctivitis Market: By Route of Administration, 2023-2033, USD (Million)
        • 12.7.1.6.4. Vernal Keratoconjunctivitis Market: By Gender, 2023-2033, USD (Million)
        • 12.7.1.6.5. Vernal Keratoconjunctivitis Market: By Distribution Channel, 2023-2033, USD (Million)

13. Latin America Vernal Keratoconjunctivitis Market, 2023-2033, USD (Million)

  • 13.1. Market Overview
  • 13.2. Vernal Keratoconjunctivitis Market: By Disease Type, 2023-2033, USD (Million)
  • 13.3. Vernal Keratoconjunctivitis Market: By Treatment, 2023-2033, USD (Million)
  • 13.4. Vernal Keratoconjunctivitis Market: By Route of Administration, 2023-2033, USD (Million)
  • 13.5. Vernal Keratoconjunctivitis Market: By Gender, 2023-2033, USD (Million)
  • 13.6. Vernal Keratoconjunctivitis Market: By Distribution Channel, 2023-2033, USD (Million)
  • 13.7. Vernal Keratoconjunctivitis Market: By Region, 2023-2033, USD (Million)
    • 13.7.1. Latin America
      • 13.7.1.1. Brazil
        • 13.7.1.1.1. Vernal Keratoconjunctivitis Market: By Disease Type, 2023-2033, USD (Million)
        • 13.7.1.1.2. Vernal Keratoconjunctivitis Market: By Treatment, 2023-2033, USD (Million)
        • 13.7.1.1.3. Vernal Keratoconjunctivitis Market: By Route of Administration, 2023-2033, USD (Million)
        • 13.7.1.1.4. Vernal Keratoconjunctivitis Market: By Gender, 2023-2033, USD (Million)
        • 13.7.1.1.5. Vernal Keratoconjunctivitis Market: By Distribution Channel, 2023-2033, USD (Million)
      • 13.7.1.2. Mexico
        • 13.7.1.2.1. Vernal Keratoconjunctivitis Market: By Disease Type, 2023-2033, USD (Million)
        • 13.7.1.2.2. Vernal Keratoconjunctivitis Market: By Treatment, 2023-2033, USD (Million)
        • 13.7.1.2.3. Vernal Keratoconjunctivitis Market: By Route of Administration, 2023-2033, USD (Million)
        • 13.7.1.2.4. Vernal Keratoconjunctivitis Market: By Gender, 2023-2033, USD (Million)
        • 13.7.1.2.5. Vernal Keratoconjunctivitis Market: By Distribution Channel, 2023-2033, USD (Million)
      • 13.7.1.3. Rest of Latin America
        • 13.7.1.3.1. Vernal Keratoconjunctivitis Market: By Disease Type, 2023-2033, USD (Million)
        • 13.7.1.3.2. Vernal Keratoconjunctivitis Market: By Treatment, 2023-2033, USD (Million)
        • 13.7.1.3.3. Vernal Keratoconjunctivitis Market: By Route of Administration, 2023-2033, USD (Million)
        • 13.7.1.3.4. Vernal Keratoconjunctivitis Market: By Gender, 2023-2033, USD (Million)
        • 13.7.1.3.5. Vernal Keratoconjunctivitis Market: By Distribution Channel, 2023-2033, USD (Million)

14. Middle East and Africa Vernal Keratoconjunctivitis Market, 2023-2033, USD (Million)

  • 14.1. Market Overview
  • 14.2. Vernal Keratoconjunctivitis Market: By Disease Type, 2023-2033, USD (Million)
  • 14.3. Vernal Keratoconjunctivitis Market: By Treatment, 2023-2033, USD (Million)
  • 14.4. Vernal Keratoconjunctivitis Market: By Route of Administration, 2023-2033, USD (Million)
  • 14.5. Vernal Keratoconjunctivitis Market: By Gender, 2023-2033, USD (Million)
  • 14.6. Vernal Keratoconjunctivitis Market: By Distribution Channel, 2023-2033, USD (Million)
  • 14.7. Vernal Keratoconjunctivitis Market: By Region, 2023-2033, USD (Million)
    • 14.7.1. Middle East and Africa
      • 14.7.1.1. GCC
        • 14.7.1.1.1. Vernal Keratoconjunctivitis Market: By Disease Type, 2023-2033, USD (Million)
        • 14.7.1.1.2. Vernal Keratoconjunctivitis Market: By Treatment, 2023-2033, USD (Million)
        • 14.7.1.1.3. Vernal Keratoconjunctivitis Market: By Route of Administration, 2023-2033, USD (Million)
        • 14.7.1.1.4. Vernal Keratoconjunctivitis Market: By Gender, 2023-2033, USD (Million)
        • 14.7.1.1.5. Vernal Keratoconjunctivitis Market: By Distribution Channel, 2023-2033, USD (Million)
      • 14.7.1.2. Africa
        • 14.7.1.2.1. Vernal Keratoconjunctivitis Market: By Disease Type, 2023-2033, USD (Million)
        • 14.7.1.2.2. Vernal Keratoconjunctivitis Market: By Treatment, 2023-2033, USD (Million)
        • 14.7.1.2.3. Vernal Keratoconjunctivitis Market: By Route of Administration, 2023-2033, USD (Million)
        • 14.7.1.2.4. Vernal Keratoconjunctivitis Market: By Gender, 2023-2033, USD (Million)
        • 14.7.1.2.5. Vernal Keratoconjunctivitis Market: By Distribution Channel, 2023-2033, USD (Million)
      • 14.7.1.3. Rest of Middle East and Africa
        • 14.7.1.3.1. Vernal Keratoconjunctivitis Market: By Disease Type, 2023-2033, USD (Million)
        • 14.7.1.3.2. Vernal Keratoconjunctivitis Market: By Treatment, 2023-2033, USD (Million)
        • 14.7.1.3.3. Vernal Keratoconjunctivitis Market: By Route of Administration, 2023-2033, USD (Million)
        • 14.7.1.3.4. Vernal Keratoconjunctivitis Market: By Gender, 2023-2033, USD (Million)
        • 14.7.1.3.5. Vernal Keratoconjunctivitis Market: By Distribution Channel, 2023-2033, USD (Million)

15. Company Profile

  • 15.1. Abbott Laboratories
  • 15.2. AbbVie
  • 15.3. Alcon
  • 15.4. Allergan
  • 15.5. Bausch Health
  • 15.6. F Hoffmann La Roche
  • 15.7. Laboratoires Thea
  • 15.8. Meda Pharmaceuticals
  • 15.9. Novartis
  • 15.10. Santen Pharmaceutical
  • 15.11. Senju Pharmaceutical
  • 15.12. Sun Pharma
  • 15.13. Teva Pharmaceuticals
  • 15.14. Other Notable Players
샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제